MME MICHELE CHEROYAN

Rhumatologue

RPPS 10000200187

✨ Profil synthétique

IA · 25/05/2026

MME MICHELE CHEROYAN est une rhumatologue qui a publié des travaux sur diverses pathologies dans le domaine de la rhumatologie. Ses publications sur PubMed couvrent une large gamme de sujets, allant des études épidémiologiques aux essais cliniques. Elle a également contribué à des revues générales et des méta-analyses, ainsi qu'à des études de cas et des analyses de données du monde réel.

Expertises présumées

Arthrite
Arthrose
Lupus érythémateux systémique
Spondylarthrite ankylosante
Rhumeumatisme psoriasique
Ostéoporose
Goutte

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib 📇 Ajouter à mes contacts

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Effectiveness of tezepelumab in severe asthma: A multicenter real-world study

European journal of internal medicine · 2026

📚 5 citations🎯 RCR 5.00🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Evidence-based management of intramural pregnancy: A comprehensive systematic review

European journal of obstetrics, gynecology, and reproductive biology · 2025

📚 2 citations

Effectiveness and safety of dual antiplatelet therapy in patients with minor ischemic stroke or transient ischemic attack and cancer: A secondary analysis of the READAPT study

European stroke journal · 2025

📚 1 citations🩺 Clinique🔓 Open Access

Lire l'abstract Crossref ↓

Abstract Introduction: Patients with ischemic stroke or transient ischemic attack (TIA) and cancer face unique risks of recurrent ischemic events and bleeding. It is unclear whether this increased risk is present even in patients with minor ischemic stroke or transient ischemic attack (TIA) receiving dual antiplatelet therapy (DAPT). This study aimed to evaluate the impact of cancer on the short-term outcomes after DAPT in patients with non-cardioembolic minor ischemic stroke or high-risk TIA. Patients and methods: This was a secondary analysis of the prospective multicentric READAPT study (NCT05476081), including patients with non-cardioembolic minor ischemic stroke (NIHSS ⩽ 5) or high-risk TIA (ABCD2 ⩾4) who initiated DAPT within 48 h of symptom onset. The primary effectiveness outcome was the 90-day risk of new ischemic stroke or other vascular events (TIA, myocardial infarction, death due to vascular causes). Secondary outcomes included 90-day mRS score distribution and all-cause mortality. The primary safety outcome was the 90-day risk of any bleeding, with secondary safety outcomes including 24-h hemorrhagic transformation. We used Inverse Probability Weighting to compare outcomes between patients with and without cancer. Results: From 2278 patients in the READAPT study cohort, we included 1561 patients (mean age 70.3 ± 11.7 years; 65.4% males), of whom 206 (13.2%) had cancer, categorized as either active (27.7%) or in remission (72.3%). After weighting, overall cancer patients had a higher risk of 90-day new ischemic stroke or other vascular events (weighted HR 1.78, 95% CI 1.20–2.63, p = 0.004) and worse 90-day mRS score distribution (OR 1.24, 95% CI 1.10–1.41, p &lt; 0.001) compared to patients without cancer. The 90-day risk of bleeding did not differ between cancer and no-cancer groups overall. When analyzing cancer subgroups, patients with active cancer had significantly higher risk of 90-day ischemic stroke or other vascular (weighted HR 2.75, 95% CI 1.70–4.45, p &lt; 0.001) and any bleeding (weighted HR 2.51, 95% CI 1.27–4.97, p = 0.008) events compared to no-cancer patients. In contrast, patients with cancer in remission had comparable risks to those without cancer. Furthermore, hematological malignancies were associated with a substantially higher risk of 90-day new ischemic stroke or other vascular events compared to solid tumors (weighted HR 8.15, 95% CI 5.06–13.14, p &lt; 0.001). Conclusions: Patients with minor ischemic stroke or high-risk TIA and active cancer have increased risk of ischemic and bleeding events after DAPT. Conversely, patients with cancer in remission have similar outcomes compared to those with no cancer.

Cookies & analyse de trafic

MME MICHELE CHEROYAN

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (28) — classées par pathologie

Transversal7

Épidémiologie & registres6

Revue générale6

Revue / méta-analyse4

Case report / série3

Vraie vie / RWE2

Essai clinique1

IRM ostéo-articulaire1

Pédiatrie1

Pharmacovigilance1

Recommandations1

SAPL1

Partager cette fiche